Li Tianquan: global new drug research and development trend through data perspective

On October 18 and 19, 2018, the International Summit Forum on frontier and practice of innovative drug discovery in 2018 was jointly sponsored by Chengdu leading drug development Co., Ltd., Pfizer Asia innovation center, MSD R & D (China), Johnson & Johnson Asia Pacific innovation center, GlaxoSmithKline and Shenzhen micro core biotechnology, and hosted by Chongqing Kangzhou big data Co., Ltd The 8th International Summit Forum on DNA coding compound library technology was held in Chengdu at the same time Adhering to the theme of "innovation, pragmatism and cooperation", more than 1000 people gathered in Chengdu to share the feast The conference invited 68 domestic and foreign heavyweight experts and scholars from government regulatory departments, academia, industry, business and venture capital circles to give keynote speeches, focusing on domestic and foreign biomedical market analysis and policy analysis, studying and judging the new trend of intelligent medical industry, discussing new targets and technologies for new drug research and development, and sharing many domestic and foreign first-line new drug research and development examples Li Tianquan, co-founder of pharmaceutical intelligence network and President of data business department, was invited to attend The following is the PPT content of his report at the 2018 International Forum on innovative drugs, which he shared with readers Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.